NTRK fusion is a driving factor in various adult and pediatric cancers, especially in certain rare tumors like infantile fibrosarcoma and secretory breast cancer, where it is highly enriched. Therefore, the future application prospects of NTRK inhibitors in this area are very promising.

Cocrystal Pharma has initiated the enrollment of the first participant in a Phase 2a clinical trial aimed at assessing the efficacy of the orally-administered CC-42344 for both pandemic and seasonal influenza A strains.

Protein drugs, also known as biologics, have revolutionized the treatment of various diseases by specifically targeting specific molecules or pathways involved in disease progression.

The Phase 3 study for Sarclisa® (isatuximab) delays disease progression in newly diagnosed multiple myeloma patients who are unsuitable for stem cell transplantation.

PARP1 inhibitors are a class of drugs that target the PARP1 enzyme, crucial for DNA repair, and are particularly effective against certain cancers.

Wave Life Sciences has launched the first stage of treatment in its RestorAATion study, which assesses the pioneering RNA editing treatment, WVE-006, aimed at combatting Alpha-1 Antitrypsin Deficiency.

Active targeting of a drug is typically achieved by conjugating it to a target entity that improves bioavailability and reduces systemic toxicity.

CatalYm Reports Promising Results for Phase 2a Trial with Visugromab Treating Late-Stage NSCLC and Bladder Cancer During the 2023 ESMO Immuno-Oncology Meeting.

PDE3 inhibitors are drugs that target the PDE3 enzyme, crucial for regulating cellular signaling pathways.

Bolt Biotherapeutics Commences Phase 2 Clinical Trial Enrollment for BDC-1001 in HER2-Positive Breast Cancer Subjects Previously Administered Enhertu.

As indicated, effective use of protein drugs can be compromised by their instability in the body, rapid rates of clearance, premature uptake by tissues and immunogenicity or antigenicity.

Coherus Showcases Early-Stage Study Results for its Novel IL-27-Specific Antibody, Casdozokitug, at ESMO's 2023 Immuno-Oncology Meeting.